Alzamend Neuro (NASDAQ:ALZN) Issues Earnings Results

Alzamend Neuro (NASDAQ:ALZN) issued its earnings results on Wednesday. The company reported ($0.04) earnings per share for the quarter, Yahoo Finance reports.

Alzamend Neuro Stock Performance

Shares of NASDAQ:ALZN opened at $0.22 on Friday. Alzamend Neuro has a twelve month low of $0.21 and a twelve month high of $1.50. The company has a 50-day moving average price of $0.37 and a two-hundred day moving average price of $0.49.

Hedge Funds Weigh In On Alzamend Neuro

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Alzamend Neuro by 6,642.3% during the third quarter. Vanguard Group Inc. now owns 4,095,775 shares of the company’s stock worth $4,874,000 after purchasing an additional 4,035,028 shares during the period. BlackRock Inc. bought a new position in Alzamend Neuro during the third quarter worth about $709,000. Geode Capital Management LLC boosted its position in Alzamend Neuro by 7.2% during the fourth quarter. Geode Capital Management LLC now owns 563,660 shares of the company’s stock worth $318,000 after purchasing an additional 37,910 shares during the period. Renaissance Technologies LLC bought a new position in shares of Alzamend Neuro in the second quarter valued at approximately $56,000. Finally, Virtu Financial LLC bought a new position in shares of Alzamend Neuro in the fourth quarter valued at approximately $35,000. Institutional investors own 6.37% of the company’s stock.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.